{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:33:14Z","timestamp":1788201194987,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Many studies demonstrated that roxadustat (FG-4592) could increase hemoglobin (Hb) levels effectively in anemia patients with chronic kidney disease (CKD). However, its safety remains controversial. This study aims to explore the risk of infection for CKD patients treated with roxadustat, especially focused on sepsis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We thoroughly searched for the randomized controlled trials (RCTs) comparing treatment with roxadustat versus erythropoiesis stimulating agents (ESAs) or placebo in PubMed, Embase, Cochrane Library,\n                    <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                    , European Union Clinical Trials Register. Both on and not on dialysis anemia patients with CKD were included. Primary outcomes contained the incidence rates of sepsis. Secondary outcomes included infection-related consequences (septic shock and other infection events), general safety outcomes [all-cause mortality, treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)] and iron parameters. Moreover, a trial sequential analysis (TSA) was conducted to assess if the results were supposed to be a robust conclusion.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Eighteen RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    = 11,305) were included. Overall, the incidence of sepsis (RR: 2.42, 95% CI [1.50, 3.89],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0003) and cellulitis (RR: 2.07, 95% CI [1.24, 3.44],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.005) were increased in the roxadustat group compared with placebo group. In non-dialysis-dependent (NDD) CKD patients, the incidence of cellulitis (RR 2.01, 95% CI [1.23, 3.28],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.005) was significantly higher in roxadustat group than that in the ESAs or placebo group. Both groups showed similar results in the incidence of septic shock (RR 1.29, 95% CI [0.86, 1.94],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.22). A significant increased risk of all-cause mortality [risk ratios (RR): 1.15, 95% confidence interval (CI) [1.05, 1.26],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002] was found in roxadustat treatment, and TSA confirmed the result. Compared with ESAs or placebo, both the incident rates of TEAEs (RR:1.03, 95% CI [1.01, 1.04],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.008) and TESAEs (RR: 1.06, 95% CI [1.02, 1.11],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002) were significantly increased in roxadustat group. As for iron parameters, changes from baseline (\u0394) of hepcidin (MD: -26.46, 95% CI [-39.83, -13.09],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0001), \u0394 ferritin and \u0394 TSAT were remarkably lower in the roxadustat group, while \u0394 Hb, \u0394 iron and \u0394 TIBC increased significantly versus those in ESAs or placebo group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    We found evidence that incidence rates of sepsis and cellulitis are higher in roxadustat group compared with placebo. This may be the result of improved iron homeostasis. The risk of all-cause mortality, TEAEs and TESAEs in CKD patients also increased in patients treated with roxadustat. We need more clinical and mechanistic studies to confirm whether roxadustat really causes infection.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.967532","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:14:09Z","timestamp":1663845249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Shan","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: A phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"B4","unstructured":"A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: Pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose -ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40560-020-00495-8","article-title":"Linkage of alterations in systemic iron homeostasis to patients' outcome in sepsis: A prospective study","volume":"8","author":"Brandtner","year":"2020","journal-title":"J. Intensive Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: A European phase 3, randomized, open-label, active-controlled study (pyrenees)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: First global approval","volume":"79","author":"Dhillon","year":"","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1224577","article-title":"Hepcidin and the iron-infection axis","volume":"338","author":"Drakesmith","year":"2012","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1681\/ASN.2021020204","article-title":"On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia","volume":"32","author":"Eleftheriadis","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fmolb.2019.00085","article-title":"Immunometabolism and sepsis: A role for HIF?","volume":"6","author":"Fitzpatrick","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103506","DOI":"10.1016\/j.resp.2020.103506","article-title":"Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury","volume":"281","author":"Han","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: Beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1021\/acs.jmedchem.7b01686","article-title":"Prolyl hydroxylase inhibitors: A breakthrough in the therapy of anemia associated with chronic diseases","volume":"61","author":"Joharapurkar","year":"2018","journal-title":"J. Med. Chem."},{"key":"B25","first-page":"91","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume-title":"Kidney Int Suppl.","author":"Kidney","year":"2013"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.4049\/jimmunol.1103471","article-title":"Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis","volume":"189","author":"Kiss","year":"2012","journal-title":"J. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD","volume":"62","author":"Kliger","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1681\/ASN.2020111664","article-title":"Roxadustat for renal anemia in ESRD from PKD patients: Is it safe enough?","volume":"32","author":"Liu","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"837249","DOI":"10.3389\/fphar.2022.837249","article-title":"Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.mam.2020.100864","article-title":"Iron in infection and immunity","volume":"75","author":"Nairz","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1073\/pnas.151179498","article-title":"Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice","volume":"98","author":"Nicolas","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor Activators in renal anemia: Current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.immuni.2015.02.001","article-title":"Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1\u03b1","volume":"42","author":"Shalova","year":"2015","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS ONE"},{"key":"B38","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"658079","DOI":"10.3389\/fphar.2021.658079","article-title":"Safe and effective treatment for anemic patients with chronic kidney disease: An updated systematic review and meta-analysis on roxadustat","volume":"12","author":"Tang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B40","unstructured":"Cardiovascular and renal drugs advisory committee meeting july 15, 2021 roxadustat2021"},{"key":"B41","unstructured":"Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis FDA Presentation2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/SHK.0b013e318231866f","article-title":"Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide","volume":"36","author":"Yeh","year":"2011","journal-title":"Shock"},{"key":"B43","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/bcp.15055","article-title":"Efficacy and safety of roxadustat for anemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis","volume":"88","author":"Zheng","year":"2021","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:14:19Z","timestamp":1663845259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":43,"alternative-id":["10.3389\/fphar.2022.967532"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.967532","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"967532"}}